Download Brochure
Table of Content
Get a Price
April 2025
Principal Consultant
Reviewed By
The global monoclonal antibodies in veterinary health market size is calculated at US$ 1.23 in 2024, grew to US$ 1.45 billion in 2025, and is projected to reach around US$ 6 billion by 2034. The market is expanding at a CAGR of 17.13% between 2025 and 2034. A growing number of domesticating animals and formation of organizations rescuing animals is driving the monoclonal antibodies in veterinary health market.
Monoclonal antibodies (mAbs) have been a cornerstone of human healthcare for nearly four decades, with applications in oncology, autoimmune diseases, and inflammatory conditions. However, mAb treatment is a relatively new but promising therapeutic technique that has been introduced in veterinary medicine, particularly for small animals. Since chronic conditions, including cancer, arthritis, allergies, and chronic pain, are frequent in dogs and cats, mAb therapy may provide these patients with the same advantages as human therapies. Pharmaceutical firms are eagerly awaiting the first veterinary biosimilars to hit the market, and several novel monoclonal antibodies (mAbs) are already being researched.
The discovery of antibodies is expected to be significantly impacted by artificial intelligence (AI) in the years to come, as is the case with other areas of research and business. It has been steadily demonstrated that AI can accurately direct various experimental phases with more resilient procedures. They may now cover the entire process of discovery. All of these experimental procedures are rapidly being replaced by AI techniques, which simplify the process and reduce attrition. Exploring the complete antibody repertoire experimentally is just not feasible. Therefore, AI-based computational methods are becoming crucial for antibody research.
Adoption of Advanced Therapeutics
One major factor propelling the worldwide monoclonal antibodies in veterinary health market is the ongoing development and uptake of cutting-edge veterinary therapies. The sector is seeing a boom in the use of innovative therapies due to the rise in pet ownership and the increased need for superior veterinary care. Additionally, monoclonal antibodies are now more widely available due to developments in biopharmaceutical technology, which has accelerated their use in the veterinary industry.
High cost
The market is subject to a number of severe limitations and difficulties. The high cost of producing monoclonal antibodies is a major obstacle that prevents their broad use, especially in markets where costs are a concern. Another obstacle is regulatory barriers, as veterinary monoclonal antibody approval can be a difficult and drawn-out procedure. This may raise development expenses and postpone market entry.
Application in New Areas
mAbs are being used to treat infectious illnesses, among other novel veterinary medical uses. By targeting certain diseases with these antibodies, the animal's immune system may be strengthened, and illnesses can be fought off more successfully. Furthermore, mAbs are being investigated for their ability to prevent infections, especially in high-risk settings like animal shelters and farms. This proactive approach to healthcare is becoming more popular as a way to enhance animal welfare and manage illness outbreaks. Researchers, veterinarians, and pharmaceutical corporations have collaborated more in the growing age of mAbs in veterinary medicine.
By animal type, the dog segment dominated the monoclonal antibodies in veterinary health market in 2024. The most popular and extensively tamed pets in the world are dogs. Around the world, one-third (33%) of homes have a do. The development of monoclonal antibodies for dogs is, therefore, rapidly expanding. Globally, parvovirus is one of the leading causes of disease and death in dogs. Canine Parvovirus Monoclonal Antibody (CPMA) is the first one-dose therapy option for parvovirus in dogs aged 8 weeks and up that has received USDA conditional approval.
By application, the dermatology segment was dominant in the monoclonal antibodies in veterinary health market in 2024. With monoclonal antibodies accounting for one-third of all newly approved medications globally, the market for these drugs is now flourishing. Immunobiologics are a reality in modern clinical practice and have become more prevalent in the context of inflammatory diseases particularly in dermatology, where there are authorized medications for psoriasis, atopic dermatitis, and hidradenitis suppurativa, in addition to several others that are being researched. Skin allergies can also be treated with it. When it comes to treating skin allergies and osteoarthritis in dogs and cats, monoclonal antibody treatments are far less likely to have negative side effects than other medications.
By application, the pain segment is estimated to grow significantly in the monoclonal antibodies in veterinary health market during the forecast period. In dogs and cats, osteoarthritis (OA) is a common cause of euthanasia, and its associated pain treatment is still difficult. As a result, anti-NGF therapy appears to be a highly promising and successful new treatment for chronic pain. In the future, anti-nerve growth factor monoclonal antibodies will be used to treat chronic pain in cats and dogs.
By end-user, the veterinary hospital segment dominated the monoclonal antibodies in veterinary health market in 2024. In the United States, veterinarians examine more than half a million animals each day. The AVMA produced a study that verified the annual number of veterinary visits, which came to 202.4 million. This corresponds to around 554,520 visitors every day. Visits to veterinary clinics and animal hospitals are being driven by the increase in the adoption of companion pets worldwide. The primary cause of this increase in adoption is the growing humanization of pets, as more and more pet owners embrace their animals as part of the family.
North America dominated the monoclonal antibodies in veterinary health market share by 44% in 2024. North America is home to top biotechnology and pharmaceutical firms that have significant investments in the development of veterinary health. By using their knowledge of human healthcare to generate tailored treatments for animals, these businesses are leading the way in the development and marketing of monoclonal antibody therapeutics. Veterinary biologics, including monoclonal antibodies, have defined clearance processes set up by North American regulatory agencies, including the U.S. Food and Drug Administration (FDA) and Health Canada. The commercial launch of novel treatments is accelerated by this simplified regulatory framework.
86.9 million households, or 66% of all households in the United States, have a pet in 2024. Over the past thirty years, pet ownership has grown dramatically. Just 56% of American households had a pet in 1988. The majority of pet owners (51%) believe that their animals are just as much a part of their family as any human member. The National Institute of Food and Agriculture (NIFA) of the U.S. Department of Agriculture (USDA) announced in September 2024 that it will invest $17.6 million to promote agricultural research that safeguards the welfare and health of farmed animals.
In October 2024, the Canadian government stated that Animal Health Canada (AHC) would receive up to $13,343,409 over five years for three initiatives. By raising the bar for emergency response, disease surveillance, and animal care, this initiative seeks to protect Canadians while improving the health and well-being of animals. Additionally, AHC will get up to $5,000,000 for a second project that will enhance emergency management procedures. In conclusion, AHC will be awarded up to $4,809,235 to review, update, and revise a number of Codes of Practice.
Asia Pacific is estimated to host the fastest-growing monoclonal antibodies in veterinary health market during the forecast period. China, India, and Japan are becoming important markets in the Asia-Pacific area. The need for cutting-edge veterinary care is fueled by rising pet ownership and rapid urbanization. Government programs to upgrade the infrastructure for animal health also quicken industry growth. The need for monoclonal antibodies in cattle is also driven by the region's agricultural industry.
The pet sector is flourishing in China. Due to rising investments and changing customer demographics, the pet sector in China is expanding quickly. Millennials and Gen Z pet owners, who value "fur babies" more than conventional family structures, are especially affected by this. The rising number of single-person families and the elderly population in China are fueling the pet industry. While 22% of families had pets in 2023—including 69.8 million cats and 51.75 million dogs in metropolitan areas—single-person households accounted for 16.77% of all households.
The updated Livestock Health and Disease Control Programme (LHDCP), which aims to improve animal healthcare and disease prevention throughout India, was approved by the Union Cabinet in March 2025 under the leadership of Prime Minister Modi. With a budget of ₹3,880 crore for 2024–2025 and 2025–2026, the redesigned plan consists of three main parts: the recently launched Pashu Aushadhi program, the National Animal Disease Control Programme (NADCP), and Livestock Health & Disease Control (LH&DC).
Europe is expected to be significantly growing in the monoclonal antibodies in veterinary health market during the forecast period. With nations like Germany, France, and the United Kingdom in the forefront, Europe comes in second. These countries place a high priority on animal health, which is reinforced by strong legal systems and significant financial support for veterinary research. The increasing demand for companion animal healthcare is good for the European market. The region's focus on disease control and animal welfare propels market expansion. The adoption of cutting-edge therapies is being aided by an increase in investment in veterinary healthcare infrastructure.
The pet industry's biggest market in the EU is in Germany. In 2023, 14 percent of German families had two or more pets, while 45 percent of households had a pet. This amounts to almost 34.3 million pets. In Germany, the veterinary administration and laws protect the health of animals. Since animal illnesses transcend national boundaries, the Federal Ministry consistently collaborates with the veterinary authorities of third-world and other Member States.
Millions of individuals in the UK must take their pets to the veterinarian for routine treatment or to handle more serious or urgent issues because pets make up 57% of all households. The UK's primary research and laboratory testing center will get a £200 million boost in December 2024, strengthening the nation's efforts to combat serious animal illnesses.
In February 2025, we are thrilled to collaborate with Nona as we continue to develop innovative, protein-based animal health treatments, said Juergen Horn, DVM, PhD, President of Invetx. Our clinical program is developing more quickly because of Nona's HCAbs, which will help us prove the effectiveness and safety of our unique technological platforms.
By Animal Type
By Application
By End-user
By Region
April 2025
March 2025
March 2025
March 2025
Schedule a Meeting